EGFR and non-small cell lung carcinoma: In addition, SNPs, MSNs, and hollow MSNs have been functionalized with epidermal growth factor receptor (EGFR), an anticancer drug target for a number of cancers, such as non-small cell lung cancer, resistance colorectal cancer, and hepatocellular carcinoma, obtaining cell growth inhibition from 64 to 85% over a range of chemo and genetic therapies [70,71,72,73].